Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Corsair Gaming Inc (CRSR) vs Novo Nordisk A/S (NVO) Price & Performance

Corsair Gaming IncTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Corsair Gaming Inc vs Novo Nordisk A/S — how do they compare? Corsair Gaming Inc trades at $12.92 (market cap $1.39B), while Novo Nordisk A/S trades at $46.42 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 149.5× Corsair Gaming Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Corsair Gaming Inc pays none. Which is the better fit depends on your goals.

CRSRNVO
Market Cap
$1.39B$207.85B
Sector
TechnologyHealth
52-Week High
$14.35$63.98
52-Week Low
$4.58$35.29
Enterprise Value
$1.38B$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Corsair Gaming Inc

Corsair Gaming (CRSR) trades at $12.92, down 5.76% in the last session, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates and raising full-year guidance, while recent acquisitions like Trak Racer and AI product launches aim to drive growth. However, the stock faces valuation concerns with a high P/E ratio of 41.39 and inconsistent profitability, as net income turned positive only in 2026 after previous losses.

The outlook is mixed: improved cash flow and strategic expansions support upside potential, but high valuation and competitive pressures pose risks. Analyst consensus is cautious with a $12.40 price target below the current price, suggesting limited near-term gains despite recent operational improvements.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.

Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Corsair Gaming Inc

Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment

Read more on CRSR

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO